Biosimilars’ Generic-style Labeling Limits Data Promotion, Companies Say
Executive Summary
Given dearth of biosimilar-specific data on label for Sandoz’s filgrastim-sndz, biosimilar sponsors say they need way to discuss their products’ analytical and clinical data with health care providers and payers, while physicians want more data about the biosimilar itself in labeling.
You may also be interested in...
Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested
New draft Q&A and three final guidances from FDA offer pros and cons for sponsors of biosimilar applications.
Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming
Group of 11 companies is focusing on biosimilar reimbursement and educational issues important to market formation.
Biosimilar But Different: Zarxio, Neupogen Diverge On Syringes, Vials
Differences in product presentation may not have much market impact now but could prove a regulatory challenge if Sandoz pursues an interchangeability determination down the line.